Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 2/20 | 0.47 |
| ▸ | HTR2B | P41595 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18347078 | 1.00 | SLC6A4 (0.47) | SLC6A4HTR2CHTR2BDRD2DRD1 | |
| SCHEMBL18347073 | 1.00 | SLC6A4 (0.47) | SLC6A4HTR2CHTR2BDRD2DRD1 | |
| SCHEMBL18347081 | 0.89 | IDO1 (0.42) | SLC6A4HTR2CHTR2BDRD2DRD1 | |
| SCHEMBL20078384 | 0.80 | SLC6A4 (0.44) | SLC6A4HTR2CHTR2BDRD2DRD1 | |
| SCHEMBL17729306 | 0.79 | IDO1 (0.42) | SLC6A4HTR2CHTR2BDRD2DRD1 | |
| SCHEMBL6482195 | 0.79 | HTR2A (0.47) | SLC6A4HTR2CHTR2BIDO1SRD5A1 | |
| SCHEMBL25904940 | 0.78 | DRD2 (0.50) | SLC6A4HTR2CHTR2BDRD2DRD1 | |
| SCHEMBL14349183 | 0.77 | HTR2C (0.38) | SLC6A4HTR2CHTR2BIDO1ALDH1A1 | |
| SCHEMBL409985 | 0.76 | ACHE (0.43) | SLC6A4HTR2CHTR2BDRD2DRD1 | |
| SCHEMBL14209228 | 0.76 | IDO1 (0.66) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951019-B2 | Therapeutic compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160376238-A1 | THERAPEUTIC COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2016-12-29 | — | — | US | disclosed |
| US-8378118-B2 | Pyrazole-based thyroid receptor compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2013-02-19 | — | — | US | disclosed |
| US-20120202816-A1 | NOVEL COMPOUNDS | TORRENT PHARMACEUTICALS, LTD. (IN) | 2012-08-09 | — | — | US | disclosed |
| US-8143424-B2 | Thyroid like compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2012-03-27 | — | — | US | disclosed |
| US-20100168110-A1 | Novel Compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376238-A1 | THERAPEUTIC COMPOUNDS | SIRT2, SIRT1, SIRT3 | SLC6A4 3701/4885HTR2C 3130/4885HTR2B 3022/4885 |
| US-20120202816-A1 | NOVEL COMPOUNDS | TSHR, THRB, GPR119 | SLC6A4 2527/4885HTR2C 1805/4885HTR2B 2187/4885 |
| US-20100168110-A1 | Novel Compounds | TSHR, THRB, GPR119 | SLC6A4 2527/4885HTR2C 1805/4885HTR2B 2187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.